Chronos Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 7

Chronos Therapeutics General Information

Description

Developer of therapeutic drugs intended to offer treatment for nervous system disorders. The company's services engage in research and development of drugs for age-related disease treatments, as well as focus on re-positioning drugs and screening, discovery and development of novel proprietary drug candidates, enabling healthcare professionals to offer advanced treatment to patients suffering from nervous disorders and ensure faster recovery for them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 26 Beaumont Street
  • Oxfordshire
  • Oxford OX1 2NP
  • England, United Kingdom
+44 01865 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Chronos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 20-Jul-2016 000.00 Completed Startup
9. Grant 01-Mar-2016 00000 000.00 Completed Startup
8. Grant 01-Jun-2015 000.00 000.00 Completed Startup
7. Grant 01-Apr-2015 0000 000.00 Completed Startup
6. Grant 01-Nov-2014 00.000 000.00 Completed Startup
5. Early Stage VC 09-Dec-2013 000.00 000.00 000.00 Completed Startup
4. Grant 01-Aug-2013 00.00 00.00 Completed Startup
3. Early Stage VC 01-Oct-2012 00.000 00.00 000.00 Completed Startup
2. Early Stage VC 01-Sep-2010 $3.95M $5.98M 000.00 Completed Startup
1. Early Stage VC 01-Jul-2009 $2.04M $2.04M 000.00 Completed Startup
To view Chronos Therapeutics’s complete valuation and funding history, request access »

Chronos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 3 0,000,000 00.000000 00.00 00.00 00.00 00.000
Ordinary 3 000,000 00.000000 00.00 00.00 00.00
Ordinary 2 0,000,000 00.000000 00.0 00.0 00.0 0.000
Ordinary 1 3,605,837 $0.000162 $1.14 $1.14 $1.14 8.73%
Ordinary 2,487,314 $0.000162 $0.81 $0.81 1x $0.81 6.02%
To view Chronos Therapeutics’s complete cap table history, request access »

Chronos Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic drugs intended to offer treatment for nervous system disorders. The company's services engage i
Drug Discovery
Oxford, United Kingdom
4 As of 2021
000.00
0000000000 0 000.00

00000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Wuerzburg, Germany
00 As of 0000
000.00
000000 - 000 000.00

000000 0

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000 000000000
Bethlehem, PA
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Chronos Therapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vasopharm Venture Capital-Backed Wuerzburg, Germany 00 000.00 000000 - 000 000.00
000000 00000000000 Venture Capital-Backed Bethlehem, PA 000.00 0000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Chronos Therapeutics Patents

Chronos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201714049-D0 New compounds Granted 01-Sep-2017 000000000
GB-2558975-B Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists Active 01-Sep-2017 000000000
GB-2558975-A New compounds Granted 01-Sep-2017 0000000000 0
JP-2019501972-A Tacrolimus for the treatment of tdp-43 proteinosis Pending 08-Jan-2016 0000000000
GB-201600376-D0 Novel therapeutic agents Ceased 08-Jan-2016 A61K31/436

Chronos Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Peter Jenner Ph.D Chief Scientific Officer
Tanya Palmer Director, Clinical Development
Huw Jones Ph.D Chief Executive Officer & Executive Chairman
Alexandre Akoulitchev Ph.D Scientific Director & Board Member
Mark Donaldson Finance Director
You’re viewing 5 of 11 executive team members. Get the full list »

Chronos Therapeutics Board Members (10)

Name Representing Role Since
Alexandre Akoulitchev Ph.D Self Scientific Director & Board Member 000 0000
Christian Millar Self Board Member 000 0000
Christopher Towler Ph.D Oxford Spin-out Equity Management Board Member 000 0000
Huw Jones Ph.D Self Chief Executive Officer & Executive Chairman 000 0000
Martin Diggle Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Chronos Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chronos Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shire Corporation Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Odey Asset Management Hedge Fund Minority 000 0000 000000 0
Odey Swan Fund Venture Capital Minority 000 0000 000000 0
UK Innovation Agency Government 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Chronos Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (0 000- 20-Jul-2016 000000000 Buildings and Property 000 00000
To view Chronos Therapeutics’s complete investments history, request access »